Keywords: AE; adverse event; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay; GMC; geometric mean concentration; GMT; geometric mean titer; PCV7; 7-valent pneumococcal conjugate vaccine; PCV13; 13-valent pneumococcal conjugate vaccine; PHiD-CV; pn
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: AOM; acute otitis media; CI; confidence interval; CRM; cross-reacting material 197; DT; diphtheria toxoid; DTaP; diphtheria, tetanus, acellular pertussis; DTwP; diphtheria, tetanus, whole-cell pertussis; dPly; detoxified pneumolysin; EPA; exotoxin A of Ps
Keywords: Acute otitis media; Pneumococcal conjugate vaccines; PHiD-CV; 13vCRM; Post-marketing surveillance; Observational studies;
Keywords: Streptococcus pneumoniae; Nasopharyngeal carriage; Pneumolysin; Pneumococcal histidine triad protein D; Vaccine efficacy; Infant; AE; adverse event; ATP; according-to-protocol; CI; confidence interval; dPly; pneumolysin toxoid; ELISA; enzyme-linked immuno
Keywords: AOM; acute otitis media; CI; confidence interval; CVE; Centro de Vigilância Epidemiológica; IAL; Instituto Adolfo Lutz; IPD; invasive pneumococcal disease; NS; statistically non-significant; NTHi; non-typeable Haemophilus influenzae; NVT; non-vaccine ty
Reduced nontypeable Haemophilus influenzae lower airway infection in children with chronic endobronchial suppuration vaccinated with the 10-valent pneumococcal H. influenzae protein D conjugate vaccine
Keywords: BAL; bronchoalveolar lavage; CFU; colony-forming units; CI; confidence interval; CSLD; chronic suppurative lung disease; HR; hazard ratio; HRCT; high-resolution computed tomography; NP; nasopharyngeal; NT; Northern Territory; NTHi; nontypeable Haemophilus
Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III
Keywords: Pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV); 1-dose vial presentation; 4-dose vial presentation; Immunologic non-inferiority; Safety; Infants; AE; adverse event; ATP; according-to-protocol; CI; confidence interva
Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study
Keywords: Pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV); Immunogenicity; Safety; Asplenia; Splenic dysfunction; AE; adverse event; ATP; according-to-protocol; CI; confidence interval; ELISA; enzyme-linked immunosorbent assay
Impact of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) on childhood pneumonia hospitalizations in Brazil two years after introduction
Keywords: PHiD-CV; 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine; NIP; National Immunization Program; PCV7; 7-valent pneumococcal conjugate vaccine; IPD; Invasive pneumococcal disease; PCV13; 13-valent pneumococcal conjugate
Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: A phase I/II randomized clinical study
Keywords: 23PPV; 23-valent pneumococcal polysaccharide vaccine; AE; adverse event; anti-PD; NTHi protein D antibody; ATP; according to protocol; dPly; pneumolysin toxoid; ELISA; enzyme-linked immunosorbent assay; GMC; geometric mean concentration; GMT; geometric me
Economic Impact of Pneumococcal Protein-D Conjugate Vaccine (PHiD-CV) on the Malaysian National Immunization Programme
Keywords: cost-effectiveness; Malaysia; nontypeable Haemophilus influenzae; PHiD-CV; pneumococcal conjugate vaccine; pneumococcal protein-D conjugate vaccine; Streptococcus pneumoniae; 13-valent pneumococcal conjugate vaccine;
Safety and immunogenicity of an investigational vaccine containing two common pneumococcal proteins in toddlers: A phase II randomized clinical trial
Keywords: Pneumococcal proteins; dPly; PhtD; Safety; Immunogenicity; Toddler vaccination; AE; adverse event; anti-PD; NTHi protein D antibody; ATP; according-to-protocol; CI; confidence interval; dPly; pneumolysin toxoid; ELISA; enzyme-linked immunosorbent assay; G
Cost-Effectiveness Analysis of Pneumococcal Vaccination with the Pneumococcal Polysaccharide NTHi Protein D Conjugate Vaccine in the Philippines
Keywords: cost-effectiveness; PCV13; PHiD-CV; Philippines; vaccination;
Immunological memory and nasopharyngeal carriage in 4-year-old children previously primed and boosted with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) with or without concomitant prophylactic paracetamo
Keywords: AE; adverse event; ATP; according-to-protocol; BS; blood sample; CPS; capsular polysaccharide; CI; confidence interval; DTPa-HBV-IPV/Hib; combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae
Sampling methods for the study of pneumococcal carriage: A systematic review
Keywords: STGG; skim milk-trypton-glucose-glycerin; SGG; skim milk-glycerol-glucose; ETA; egg-thioglycolate-antibiotic media; PCR; polymerase chain reaction; WHO; World Health Organisation; PCV-7; 7-valent pneumococcal conjugate vaccine; PCV-13; 13-valent pneumococ
Comparing Health Outcomes and Costs of General Vaccination with Pneumococcal Conjugate Vaccines in Sweden: A Markov Model
Keywords: cost-effectiveness analysis; costs; health outcomes; PHiD-CV; PCV13; pneumococcal disease; vaccine
The potential cost-effectiveness of infant pneumococcal vaccines in Australia
Keywords: 3Â +Â 0; vaccine dose schedule of 3 infant doses without toddler booster dose; 3Â +Â 1; vaccine dose schedule of 3 infant doses and one toddler dose; AIHW; Australian Institute of Health and Welfare; AR-DRG; Australian refined-diagnosis related group; BEA
Economic evaluation of second generation pneumococcal conjugate vaccines in Norway
Keywords: Pneumococcal conjugate vaccine; PCV7; PCV13; PHiD-CV; Cost-effectiveness; Meningitis; Bacteraemia; Pneumonia; Acute otitis media; Norway;